title: Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders.
abstract: OBJECTIVE
  Treatment guidelines for type 2 diabetes mellitus (T2DM) suggest weight loss as a means to maintain glycemic control. Lorcaserin has been approved for chronic weight management in the United States as an adjunct to a reduced-calorie diet and exercise, and the previous phase 3 Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus (BLOOM-DM) study has shown that, in addition to weight loss, lorcaserin is associated with improvements in glycemic parameters. In this post hoc analysis of the BLOOM-DM trial, the relationship between responder status (patients achieving ≥5% weight loss at Week 52) and glycemic and cardiometabolic parameters is evaluated.
  
  
  METHODS
  Data are presented for patients receiving lorcaserin 10 mg twice daily or placebo for 52 weeks.
  
  
  RESULTS
  More than twice as many patients receiving lorcaserin plus diet and exercise counseling were classified as Week 52 responders compared to those receiving diet and exercise counseling alone (37.5% vs. 16.1%, respectively; p < 0.001), and lorcaserin Week 52 responders had greater improvements vs. placebo Week 52 responders in FPG (-38.1 mg/dL vs. -26.0 mg/dL) and HbA1c (-1.3% vs. -1.0%). Furthermore, more lorcaserin-treated Week 52 responders decreased the number of concomitant oral antidiabetic medications (OADs) used, and fewer increased the number of OADs used, compared to placebo. Unexpectedly, lorcaserin Week 52 nonresponders also had substantial reductions in glycemic levels, despite very modest weight loss.
  
  
  CONCLUSIONS
  These data support lorcaserin use in overweight and obese patients with T2DM to promote weight loss and facilitate glycemic control.
  
  
  BACKGROUND
  www.clinicaltrials.gov identifier is NCT00603291.
authors.affiliation: a Division of Endocrinology , Columbia University Medical Center , New York , NY , USA.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pi-Sunyer
authors.affiliation: b Formerly of the division of Preclinical and Clinical Drug Development , Arena Pharmaceuticals, Inc ., San Diego , CA , USA.
authors.forename: William
authors.initials: W
authors.lastname: Shanahan
authors.affiliation: c Formerly of the Global Neuroscience Business Unit, Eisai Inc ., Woodcliff Lake , NJ , USA.
authors.forename: Randi
authors.initials: R
authors.lastname: Fain
authors.affiliation: c Formerly of the Global Neuroscience Business Unit, Eisai Inc ., Woodcliff Lake , NJ , USA.
authors.forename: Tony
authors.initials: T
authors.lastname: Ma
authors.affiliation: d Department of Nutrition Sciences , University of Alabama at Birmingham, and the Birmingham VA Medical Center , Birmingham , AL , USA.
authors.forename: W Timothy
authors.initials: WT
authors.lastname: Garvey
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001552:Benzazepines / Q000627:therapeutic use*; D001786:Blood Glucose; D015992:Body Mass Index; D003376:Counseling; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004032:Diet; D004311:Double-Blind Method; D015444:Exercise; D005260:Female; D006442:Glycated Hemoglobin; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000628:therapy; D050177:Overweight / Q000188:drug therapy* / Q000628:therapy; D044469:Racial Groups; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D015431:Weight Loss / Q000187:drug effects; D055815:Young Adult
chemical_list: D001552:Benzazepines; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D017366:Serotonin Receptor Agonists; C506658:lorcaserin
keywords: Obesity; diabetes mellitus; lorcaserin; overweight; weight loss